Ramipril
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
ACE Inhibitors | Ramipril | 1.25mg-5mg PO Q24H | Administer Post HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
416 | 35 | 8-10 | 14-16 | 73 (ramiprilat) | 1.2 | 23.3 | Minimal (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00178
- Fillastre J, Baguet J, Dubois D, et al. Kinetics, Safety, and Efficacy of Ramipril after Long-Term Administration in Hemodialyzed Patients. Journal of Cardiovascular Pharmacology. 1996;27(2):269-274.
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007;27(5):522-9.